Recently, therapeutic breakthroughs, gene-replacement therapy using viral delivery [3] and altering SMN2 splicing using antisense oligonucleotides [4], have remarkably improved motor function and survival of SMA patients, but patients remain prone to cardiopulmonary complications leading to opportunistic upper respiratory tract infections [5]. Here, SMN2 is linked to proximal spinal muscular atrophy.